Boehringer Ingelheim Pharmaceuticals GmbH., of Ingelheim, Germany, said the FDA granted priority review to the biologics license application for idarucizumab, which is being investigated to specifically reverse the anticoagulant effect of dabigatran, the active ingredient in Boehringer's Pradaxa in patients needing emergency intervention or experiencing an uncontrolled or life-threatening bleeding event.